Rankings
▼
Calendar
EVAX
Evaxion Biotech A/S
$20M
Q4 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$8M
Net Income
-$8M
EPS (Diluted)
$-15.44
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$40M
Total Liabilities
$8M
Stockholders' Equity
$32M
Cash & Equivalents
$32M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$8M
-$5M
-66.2%
Net Income
-$8M
-$4M
-96.3%
← FY 2021
All Quarters
Q1 2022 →
EVAX Q4 2021 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena